Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) Research & Development (2016 - 2025)

Dare Bioscience (DARE) has disclosed Research & Development for 11 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 56.18% year-over-year to $1.2 million, compared with a TTM value of $8.2 million through Sep 2025, down 44.39%, and an annual FY2024 reading of $14.2 million, down 34.05% over the prior year.
  • Research & Development was $1.2 million for Q3 2025 at Dare Bioscience, down from $1.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $13.0 million in Q4 2022 and bottomed at $1.2 million in Q3 2025.
  • Average Research & Development over 5 years is $5.3 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Research & Development soared 140.7% in 2021, then plummeted 71.04% in 2025.
  • Year by year, Research & Development stood at $7.1 million in 2021, then surged by 82.35% to $13.0 million in 2022, then plummeted by 70.72% to $3.8 million in 2023, then fell by 12.85% to $3.3 million in 2024, then tumbled by 64.51% to $1.2 million in 2025.
  • Business Quant data shows Research & Development for DARE at $1.2 million in Q3 2025, $1.4 million in Q2 2025, and $2.3 million in Q1 2025.